Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas

Journal of the National Cancer Institute

Volumn 106, Issue 1, 2014, Pages

  Yamamoto, Hiromasa ^a   Higasa, Koichiro ^d   Sakaguchi, Masakiyo ^e   Shien, Kazuhiko ^a,b   Soh, Junichi ^a   Ichimura, Koichi ^b   Furukawa, Masashi ^a   Hashida, Shinsuke ^a   Tsukuda, Kazunori ^a,b   Takigawa, Nagio ^e   Matsuo, Keitaro ^f   Kiura, Katsuyuki ^c   Miyoshi, Shinichiro ^a   Matsuda, Fumihiko ^c   Toyooka, Shinichi ^b  

^a Breast and Endocrinological Surgery ^*  (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY   (Japan)

^e KAWASAKI MEDICAL SCHOOL   (Japan)

^f KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN KINASE B; SYNAPTOPHYSIN; ASPARTIC ACID; ERBB2 PROTEIN, HUMAN; GLUTAMIC ACID; GLYCINE; VALINE;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CANCER SURGERY; CASE REPORT; CELL PROLIFERATION; CONTROLLED STUDY; DIMERIZATION; ENZYME ACTIVATION; EXON; FAMILIAL CANCER; FEMALE; GENE; HER2 GENE; HUMAN; HUMAN TISSUE; JAPANESE; LOBECTOMY; LUNG ADENOCARCINOMA; LUNG RESECTION; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PEDIGREE ANALYSIS; PLEURA METASTASIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STABILITY; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SMOKING; SOMATIC MUTATION; WILD TYPE; ADENOCARCINOMA; ASIAN; GENETIC PREDISPOSITION; GENETICS; JAPAN; LUNG TUMOR; MALE; MUTATION; PEDIGREE;

ADENOCARCINOMA; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; ASPARTIC ACID; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; GLUTAMIC ACID; GLYCINE; HUMANS; JAPAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; PEDIGREE; RECEPTOR, ERBB-2; VALINE;

EID: 84892666476     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt338     Document Type: Article

References (15)

1. Bell DW, Gore I, Okimoto RA, et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet. 2005;37(12):1315-1316.
2. Ikeda K, Nomori H, Mori T, Sasaki J, Kobayashi T. Novel germline mutation: EGFR V843I in patient with multiple lung adenocarcinomas and family members with lung cancer. Ann Thorac Surg. 2008;85(4):1430-1432.
3. Ohtsuka K, Ohnishi H, Kurai D, et al. Familial lung adenocarcinoma caused by the EGFR V843I germ-line mutation. J Clin Oncol. 2011;29(8):e191-e192.
4. van Noesel J, van der Ven WH, van Os TA, et al. Activating germline R776H mutation in the epidermal growth factor receptor associated with lung cancer with squamous differentiation. J Clin Oncol. 2013;31(10):e161-e164.
5. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12(2):175-180.
6. Shigematsu H, Takahashi T, Nomura M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 2005;65(5):1642-1646.
7. Stephens P, Hunter C, Bignell G, et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature. 2004;431(7008):525-526.
8. Bargmann CI, Hung MC, Weinberg RA. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell. 1986;45(5):649-657.
9. Bocharov EV, Mineev KS, Volynsky PE, et al. Spatial structure of the dimeric transmembrane domain of the growth factor receptor ErbB2 presumably corresponding to the receptor active state. J Biol Chem. 2008;283(11):6950-6956.
10. Fleishman SJ, Schlessinger J, Ben-Tal N. A putative molecular-activation switch in the transmembrane domain of erbB2. Proc Natl Acad Sci USA. 2002;99(25):15937-15940.
11. Mineev KS, Bocharov EV, Pustovalova YE, Bocharova OV, Chupin VV, Arseniev AS. Spatial structure of the transmembrane domain heterodimer of ErbB1 and ErbB2 receptor tyrosine kinases. J Mol Biol. 2010;400(2):231-243.
12. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9(7):463-475.
13. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9(8):550-562.
14. Mountzios G, Planchard D, Besse B, et al. Mitogen-activated protein kinase activation in lung adenocarcinoma: a comparative study between ever smokers and never smokers. Clin Cancer Res. 2008;14(13):4096-4102.
15. Planchard D, Camara-Clayette V, Dorvault N, Soria JC, Fouret P. p38 Mitogen-activated protein kinase signaling, ERCC1 expression, and viability of lung cancer cells from never or light smoker patients. Cancer. 2012;118(20):5015-5025.